Meeting
2014 ASCO Annual Meeting
Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC).
Authors
Atsushi Nakamura
Sendai Kousei Hospital, Sendai, Japan
Atsushi Nakamura , Akira Inoue , Makoto Maemondo , Yoshiaki Mori , Satoshi Oizumi , Masao Harada , Shingo Takanashi , Naoto Morikawa , Takashi Ishida , Ichiro Kinoshita , Hiroshi Watanabe , Toshiro Suzuki , Taku Nakagawa , Ryota Saito , Toshihiro Nukiwa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000002617
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7520)
DOI
10.1200/jco.2014.32.15_suppl.7520
Abstract #
7520
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
First Author: Yosuke Kawashima
Poster
2020 ASCO Virtual Scientific Program
The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: Results from a phase II single-arm trial.
First Author: Pengbo Deng
Poster
2016 ASCO Annual Meeting
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
First Author: Anne C. Chiang